Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD involves multiple biological changes, including insulin resistance, oxidative stress, inflammation, as well as genetic and environmental factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tingli, Yan, Wenhui, Cui, Xin, Liu, Na, Wei, Xiaotong, Sun, Yuzhuo, Fan, KeXin, Liu, Jieyun, Zhu, Yuanyuan, Wang, Zhuanzhuan, Zhang, Yilei, Chen, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540362/
https://www.ncbi.nlm.nih.gov/pubmed/37770820
http://dx.doi.org/10.1186/s10020-023-00721-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540362/
https://www.ncbi.nlm.nih.gov/pubmed/37770820
http://dx.doi.org/10.1186/s10020-023-00721-7

Ejemplares similares